패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Vext Science, Inc. 7 애널리스트 중 4 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Shaan Mir	Canaccord Genuity
Matt Bottomley	Canaccord Genuity
Ty Collin	Eight Capital

Vext Science 대차 대조표 상태

재무 상태 기준 확인 2/6

주요 정보

최근 재무 상태 업데이트

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its Debt

Vext Science (CSE:VEXT) Seems To Use Debt Quite Sensibly

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Is Vext Science (CSE:VEXT) A Risky Investment?

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024

It's Down 26% But Vext Science, Inc. (CSE:VEXT) Could Be Riskier Than It Looks

Vext Science, Inc., Annual General Meeting, Dec 13, 2024

Price target decreased by 14% to CA$0.57

Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023)

Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024

Price target increased by 12% to CA$0.75

Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% Cheaper

Chief Financial Officer recently bought CA$63k worth of stock

Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024

New minor risk - Earnings quality

Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024

New major risk - Shareholder dilution

Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive Role

There Is A Reason Vext Science, Inc.'s (CSE:VEXT) Price Is Undemanding

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023

Vext Science, Inc., Annual General Meeting, Dec 15, 2023

New major risk - Shareholder dilution

Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.

Is Now The Time To Put Vext Science (CSE:VEXT) On Your Watchlist?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Vext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023

First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022)

Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023

Price target increased by 7.2% to CA$1.30

Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021)

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Less than half of directors are independent

Vext Science, Inc. (CNSX:VEXT) entered into agreement to acquire Appalachian Pharm Processing, LLC for $12.5 million.

Vext Science, Inc. Announces Board Changes

Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For Now

Price target decreased to CA$1.24

Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021)

Less than half of directors are independent

Vext Science, Inc. to Report Q3, 2022 Results on Nov 17, 2022

Price target decreased to CA$1.46

Vext Science, Inc., Annual General Meeting, Dec 15, 2022

We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its Debt

Vext Science Announces Filing of Provisional Patent Application

Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. acquired a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen for $3 million.

Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021)

Director recently bought CA$53k worth of stock

Vext Science, Inc. to Report Q2, 2022 Results on Aug 24, 2022

Vext Science, Inc. Announces CFO Transition

First quarter 2022 earnings released

Vext Science, Inc. to Report Q1, 2022 Results on May 30, 2022

Vext Science (CSE:VEXT) Seems To Use Debt Quite Sensibly

Price target decreased to CA$1.84

Less than half of directors are independent

Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020)

Vext Science, Inc. Announces Executive Changes

Vext Science, Inc. to Report Q4, 2021 Results on Apr 20, 2022

Price target decreased to CA$1.99

Less than half of directors are independent

Vext Science, Inc. Appoints Mark W. Opzoomer as Board of Director

Third quarter 2021 earnings released

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released

Is Vext Science (CSE:VEXT) A Risky Investment?

Vext Science, Inc. (CNSX:VEXT) completed the acquisition of a 72,000 square foot industrial facility in Eloy, Arizona.

First quarter 2021 earnings released

Weak Statutory Earnings May Not Tell The Whole Story For Vext Science (CSE:VEXT)

Full year 2020 earnings released